9th Drug Chemistry Conference, Antalya, Türkiye, 8 - 11 Nisan 2021, ss.68
Lipogenesis is an important defining feature of overweight and obesity. These conditions, particularly
in the presence of excess fat are in some visceral area or in the ectopic locations, are associated with
health risk factors such as dyslipidemia, insulin resistance, or hypertension [1]. Hepatic steatosis refers
to excessive lipid accumulation in the liver and ectopic area. CCAAT/enhancer-binding protein alpha
(CEBPA) and Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1 Alpha (PGC1A) is a
transcription factor that plays a vital role in hepatic de novo lipogenesis, thermogenesis, mitochondrial
biogenesis and cholesterol metabolism. PGC1A interacts with Peroxisome proliferator-activated
receptor gamma (PPAR-γ), which permits the interaction of this protein with multiple transcription
factors. The genes activated by PPAR-γ induce lipid uptake and adipogenesis by fat cells [2].
In the last few years, Anti-lipogenesis activities of carotenoids have been shown in a number of preclinical studies, and its metabolic interactions have begun to be explained, suggesting these
compounds may help obesity prevention and treatment. The keto-carotenoid deinoxanthin is a unique
xanthophyll that provides greater antioxidant effects compared to other carotenoids due to its
superior scavenging activity against reactive oxygen species can only derived from Deinococcus spp [3,
4].
This study was designed to investigate the effect of deinoxanthin on hepatic steatosis in male Wistar
rats. Animals were randomly divided into three groups (n=8/group) and treated orally with distilled
water (0.25 ml-group 1) or deinoxanthin (50 μg/day-group 2, 100μg/day-group 3) for 56 days.
Thereafter, blood and liver samples were collected and have been examined for level of CEBPA and
PGC-1α. The effect of deinoxanthin on the mRNA and protein expression of PGC-1α and CEBPA were
analyzed by RT-qPCR and ELISA. Deinoxanthin treatment also decreased expression of PGC-1α and
CEBPA.